Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT
Phathom Pharmaceuticals — Q2 2025 Earnings Presentation
14 slides from Phathom Pharmaceuticals's earnings presentation, Aug 7, 2025
Slide 1: Second Quarter 2025 Earnings Conference Call
SECOND QUARTER 2025 EARNINGS CONFERENCE CALL AUGUST 2025 NASDAQ: PHAT
Slide 2: Today's Agenda
Today’s Business Update Steven Basta, President & Chief Executive Officer Agenda Q2 2025 Financial Results Robert Breedlove, VP of Finance & Principal Accounting Officer Closing Remarks Steven Basta, President & Chief Executive Officer Question & Answer Steven Basta, President & Chief Executive Offi
Slide 3: Safe harbor
Safe harbor This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our plans, expectations and goals for commercialization of VOQUEZNA and potential results of our commercializatio
Slide 4: Business Update
Business Update Steven Basta, President & Chief Executive Officer 4
Slide 5: Filled VOQUEZNA prescriptions are growing meaningfully
Filled VOQUEZNA prescriptions are growing meaningfully Quarterly Filled Prescriptions1 ~36% ~173,000 580,000 + ~118,000 ~127,000 Filled Prescriptions ~69,000 Launch-to-Date as of 7/25/251 ~35,000 Previously: 390,000+ (as of 4/18/25) ~9,500 Q1 Q2 Q3 Q4 Q1 Q2 2024 2024 2024 2024 2025 2025 1 IQVIA + Bl
Slide 6: Continued growth in cumulative writers; Q3 focus shifting to GI writing depth
Continued growth in cumulative writers; Q3 focus shifting to GI writing depth Quarterly Cumulative Writers1 GI PCP2 ~24% ~28,300 29,300 + ~17,800 ~22,800 Cumulative Writers ~12,400 Launch-to-Date ~7,250 as of 7/18/251 ~2,900 Previously: 23,600+ (as of 4/11/25) Q1 Q2 Q3 Q4 Q1 Q2 2024 2024 2024 2024 2
Slide 7: Q3 sales target realignment
Q3 sales target realignment Launch-to-Date Q3 2025: Increasing Calls Volume by Specialty1 on High-Value Sales Targets ~37K HCPs 30% 2 PCP • Nearly all GIs 70% GI • All existing writers • High decile PCPs 1 IQVIA + BlinkRx as of 7/18/25 (launch-to-date data reflects IQVIA restatements). 7 2 Includes
Slide 8: Rapid, potent, durable acid suppression profile
RAPID POTENT DURABLE acid suppression profile 8
Slide 9: Financial guidance for 2025
Financial guidance for 2025 FY 2025 Q3 2025 Q4 2025 $165M to <$60M <$55M $175M net revenues non-GAAP non-GAAP operating expense1 operating expense1 9 1 Forecast excluding stock-based compensation and other non-cash items.
Slide 10: Rapid, potent, durable acid suppression profile
RAPID POTENT DURABLE acid suppression profile 10
Slide 11: Q2 2025 Financial Results
Q2 2025 Financial Results Robert Breedlove, VP of Finance & Principal Accounting Officer 11
Slide 12: Key financial measures: cash, net revenues, and operating expenses
Key financial measures: cash, net revenues, and operating expenses in cash and $149.6M cash equivalents as of June 30, 2025 We anticipate reaching profitability in 20261 Quarterly Net Revenue Quarterly Operating Expenses Non-GAAP SG&A Non-GAAP R&D Stock-based compensation $40M $39.5 $120M $103.7 $10
Slide 13: Closing Remarks
Closing Remarks Steven Basta, President & Chief Executive Officer 13
Slide 14: Question & Answer
Question & Answer Steven Basta, President & Chief Executive Officer Robert Breedlove, VP of Finance & Principal Accounting Officer 14
Phathom Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix